Bruker’s (BRKR) Neutral Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their neutral rating on shares of Bruker (NASDAQ:BRKR) in a report published on Wednesday, Marketbeat.com reports. The brokerage currently has a $60.00 target price on the medical research company’s stock.

Several other analysts have also recently issued reports on BRKR. Zacks Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Guggenheim increased their target price on Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Stifel Nicolaus set a $50.00 target price on Bruker in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. Finally, UBS Group began coverage on Bruker in a report on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus target price of $59.43.

Bruker Trading Down 3.1%

NASDAQ BRKR opened at $54.80 on Wednesday. The company has a market capitalization of $8.35 billion, a price-to-earnings ratio of -78.29, a price-to-earnings-growth ratio of 1.73 and a beta of 1.22. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. Bruker has a 12 month low of $32.37 and a 12 month high of $66.98. The company’s fifty day moving average price is $58.79 and its two-hundred day moving average price is $53.35.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the business earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s payout ratio is -28.57%.

Insider Buying and Selling at Bruker

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 27.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bruker

Large investors have recently bought and sold shares of the business. Pallas Capital Advisors LLC bought a new position in shares of Bruker during the second quarter valued at approximately $570,746,000. Edmond DE Rothschild Holding S.A. acquired a new position in Bruker during the 2nd quarter valued at approximately $169,899,000. Primecap Management Co. CA acquired a new position in Bruker during the 2nd quarter valued at approximately $53,145,000. Bank of New York Mellon Corp acquired a new position in Bruker during the 2nd quarter valued at approximately $44,839,000. Finally, Old West Investment Management LLC bought a new position in Bruker during the 2nd quarter worth $40,146,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company’s portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.